LGNDLigand Pharmaceuticals Incorporated
Price
+81%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growth steady, the market undecided.
We are a biopharmaceutical royalty company focused on deploying capital and licensing technologies to acquire and create diversified royalty streams from high-value medicines. Our primary business is investing in and structuring royalty interests in mid- to late-stage development and commercial biopharmaceutical products, allowing us to generate long-duration, non-dilutive cash flows supported by a lean corporate cost structure.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ligand Pharmaceuticals Incorporated (LGND) reported revenue of $64M in Q2 2026 (quarter ended Jun 30, 2026), up 34% from the same quarter a year earlier. That came with net income of $49M (76% of revenue). For the full year FY2025, revenue was $268M (+60% year on year) and net income $124M. Its largest product in Q2 2026 was Material Sales Captisol at $8.0M, 12.2% of the disclosed total, just ahead of Contract Revenue And Income at 11.7%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 2, 2026Condensed Consolidated Financial Statements.Material event (exhibits only) · press release
- Aug 6, 2026Ligand Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jul 14, 2026On July 14, 2026, Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Company”), completed its previously announced merger pursuant to the terms of that certain Agreement and Plan of Merger, dated April 27, 2026, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated May 16, 2026 (as …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $65.5MThe company’s own SEC segment disclosure.
- Material Sales Captisol$8.0M12%
- Contract Revenue And Income$7.7M12%
- Contract Revenue And Other Income$7.7M12%
- Kyprolis$7.0M11%
- QARZIBA$6.2M9%
- Contract And Revenue Income Other$5.0M8%
- Other (9)$24.0M37%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.